Acadian Asset Management
SGMT icon

Acadian Asset Management’s Sagimet Biosciences SGMT Stock Holding History

Acadian Asset Management’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29,636
Closed -$154K – 2211
2026
Q1 		$154K Buy
29,636
+21,656
+271% +$121K ﹤0.01% 1648
2025
Q4 		$46K Buy
+7,980
New +$57.3K ﹤0.01% 1806
2024
Q4 		– Sell
-81,777
Closed -$225K – 2105
2024
Q3 		$225K Buy
81,777
+13,326
+19% +$41.1K ﹤0.01% 1326
2024
Q2 		$232K Buy
68,451
+33,522
+96% +$154K ﹤0.01% 1395
2024
Q1 		$188K Buy
+34,929
New +$251K ﹤0.01% 1193

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Acadian Asset Management's SGMT Position: Q2 2026 in Review

Acadian Asset Management sold out of Sagimet Biosciences (SGMT) in Q2 2026, closing a stake of 29,636 shares — an estimated $154K sold.

Acadian Asset Management first reported a position in SGMT in Q1 2024 and held it in 5 quarters. The position peaked at $232K in Q2 2024. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Acadian Asset Management reported no remaining Sagimet Biosciences position as of Q2 2026 after selling out during the quarter.
  • Acadian Asset Management sold 29,636 Sagimet Biosciences shares in Q2 2026, an estimated $154K.
  • Acadian Asset Management first reported a position in Sagimet Biosciences in Q1 2024 and held it in 5 quarters.
  • Acadian Asset Management's Sagimet Biosciences position peaked at $232K in Q2 2024.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.